Overview

A Study of JNS020QD in Patients With Chronic Pain

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of JNS020QD in patients with moderate to severe chronic pain who switched from opioid analgesics, as well as the safety and efficacy of long-term treatment (52 weeks) after switching to JNS020QD.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Pharmaceutical K.K.